Drug Trial Radar · NCT02565914
A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation
Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,131
Actual
Start
Aug 2015
Primary completion
May 2019
Study completion Dec 5, 2022
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Oct 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, open-label, 3-part rollover study in subjects with CF who are homozygous or heterozygous for the F508del-CFTR mutation and who participated in studies VX13-661-103 (Study 103, NCT02070744), VX14-661-106 (Study 106, NCT02347657), VX14-661-107 (Study 107, NCT02516410), VX14-661-108 (Study 108, NCT02392234), VX14-661-109 (Study 109, NCT02412111), VX14-661-111 (Study 111, NCT02508207), VX15-661-112 (NCT02730208), and VX16-661-114 (NCT03150719). The study is designed to evaluate the safety and efficacy of long-term treatment of VX-661 in combination with ivacaftor.
Conditions
- Cystic Fibrosis
Interventions
TEZ/IVADrug
Fixed dose tablet for oral administration.
IVADrug
Tablet for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Week 100
- Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEsTime frame: Day 1 up to Week 100
- Part C: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Week 196
Locations
154 sites in 16 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Oakland, California
Site not named
Palo Alto, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
Aurora, Colorado
Site not named
Denver, Colorado
Site not named
Gainesville, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Pensacola, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Boise, Idaho
Site not named
Chicago, Illinois
Site not named
Glenview, Illinois
Site not named
Niles, Illinois
Site not named
Peoria, Illinois
Site not named
Indianapolis, Indiana
Site not named
Iowa City, Iowa
Site not named
Lexington, Kentucky
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Detroit, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Lebanon, New Hampshire
Site not named
Long Branch, New Jersey
Site not named
New Brunswick, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Albany, New York
Site not named
Buffalo, New York
Showing 40 of 154 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.